Hansa Biopharma
Sweden - LundPharmaceutical
Focus: Hansa Biopharma is a Swedish-based public company focused on novel immunomodulatory enzymes targeting transplantation and acute autoimmune diseases. The company operates in the niche but high-value immunology space with a concentrated pipeline around kidney transplant indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Hansa Biopharma
AI assessmentNot HiringNo open roles listed right now. Follow Hansa Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Imlifidase administered in the ConfIdeS study
Kidney Transplantation in Highly Sensitized PatientsClinical Trials (1)
NCT05714514Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
N/AHelp build intelligence for Hansa Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.